US3254124A
(en)
|
1962-06-29 |
1966-05-31 |
Parke Davis & Co |
Aminoketones and methods for their production
|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
US4670459A
(en)
|
1984-10-03 |
1987-06-02 |
Merrell Dow Pharmaceuticals Inc. |
Method of alleviating withdrawal symptoms
|
US5679714A
(en)
|
1995-06-07 |
1997-10-21 |
Weg; Stuart L. |
Administration of ketamine for detoxification and treatment of tobacco addiction
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
DE19619665C2
(de)
|
1996-05-15 |
2001-03-08 |
Goedecke Ag |
Racemattrennung von Ketamin
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
US7001609B1
(en)
|
1998-10-02 |
2006-02-21 |
Regents Of The University Of Minnesota |
Mucosal originated drug delivery systems and animal applications
|
US6382204B1
(en)
|
1999-10-14 |
2002-05-07 |
Becton Dickinson And Company |
Drug delivery system including holder and drug container
|
US6962151B1
(en)
|
1999-11-05 |
2005-11-08 |
Pari GmbH Spezialisten für effektive Inhalation |
Inhalation nebulizer
|
EP1257648B2
(en)
|
2000-02-23 |
2016-09-14 |
Amgen Inc. |
Antagonistic selective binding agents of osteoprotegerin binding protein
|
BRPI0002693B8
(pt)
|
2000-06-19 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
AU2003268026A1
(en)
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
EP1567145B1
(en)
|
2002-11-18 |
2009-06-03 |
Yaupon Therapeutics, Inc. |
Analgesic uses of (s)-norketamine
|
US7713440B2
(en)
|
2003-10-08 |
2010-05-11 |
Lyotropic Therapeutics, Inc. |
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
US7928132B2
(en)
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
US20090246255A1
(en)
|
2005-09-28 |
2009-10-01 |
Thomas Meyer |
Pharmaceutical Compositions for the Treatment of Inner Ear Disorders
|
CN101466364A
(zh)
|
2006-03-22 |
2009-06-24 |
纽约大学西奈山医学院 |
鼻内施用氯胺酮治疗抑郁症
|
EP2139848A1
(en)
|
2007-04-26 |
2010-01-06 |
Auspex Pharmaceuticals, Inc. |
Deuterium labelled ketamine
|
US20110038807A1
(en)
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2013138322A1
(en)
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
AU2013305580A1
(en)
|
2012-08-23 |
2015-04-09 |
Stuart L. Weg |
Anxiolytic composition, formulation and method of use
|
PE20200404A1
(es)
|
2013-03-15 |
2020-02-26 |
Janssen Pharmaceutica Nv |
Composicion farmaceutica de clorhidrato de s-ketamina
|
US20140275276A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
WO2014169272A1
(en)
|
2013-04-12 |
2014-10-16 |
Icahn School Of Medicine At Mount Sinai |
Method for treating post-traumatic stress disorder
|
US9872841B2
(en)
|
2013-09-13 |
2018-01-23 |
National University Corporation Chiba University |
Application of R-ketamine and salt thereof as pharmaceuticals
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
WO2015108985A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
EP3130582B8
(en)
|
2014-04-29 |
2019-01-02 |
The Catholic University of Korea Industry-Academic Cooperation Foundation |
Compound having immune disease treatment effect and use thereof
|
WO2016025581A1
(en)
|
2014-08-13 |
2016-02-18 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
RS65411B1
(sr)
|
2014-11-04 |
2024-05-31 |
Acadia Pharm Inc |
Jedinjenja neuroatenuirajućeg norketamina i metodi
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
CA2989319C
(en)
|
2015-06-19 |
2019-02-05 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for anesthesiological applications
|
US20200297734A1
(en)
|
2015-06-19 |
2020-09-24 |
Melt Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for anesthesiological applications
|
EP3297620A4
(en)
|
2015-06-27 |
2019-01-09 |
Shenox Pharmaceuticals, LLC |
TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
|
US11110070B2
(en)
|
2015-11-17 |
2021-09-07 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
WO2017165877A1
(en)
|
2016-03-25 |
2017-09-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
JP6327591B2
(ja)
|
2016-08-12 |
2018-05-23 |
マツダ株式会社 |
ディーゼルエンジンの制御方法及び制御システム
|
US20200261442A1
(en)
|
2016-08-26 |
2020-08-20 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
CN109890371A
(zh)
|
2016-08-26 |
2019-06-14 |
斯瑞尼瓦萨饶·韦帕切杜 |
组合物及其方法
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
CN110325231B
(zh)
|
2016-12-27 |
2020-10-02 |
阿克申医药科技有限公司 |
用于注射药物的设备和方法
|
JP6926383B2
(ja)
|
2017-01-31 |
2021-08-25 |
日本製紙クレシア株式会社 |
吸収性補助パッド及びその使用方法
|
US11478467B2
(en)
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
BR112019024802A2
(pt)
|
2017-05-25 |
2020-07-21 |
Glytech Llc. |
terapia combinada para transtornos neuropsiquiátricos responsivos ao antagonista de nmdar
|
EP3641742A2
(en)
|
2017-06-23 |
2020-04-29 |
Develco Pharma Schweiz AG |
Hydroxynorketamine for the use in the treatment of depression
|
TW201919595A
(zh)
|
2017-09-27 |
2019-06-01 |
國立大學法人千葉大學 |
作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
|
US10869838B2
(en)
|
2017-10-10 |
2020-12-22 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
US10441544B2
(en)
|
2017-10-10 |
2019-10-15 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
WO2019094757A1
(en)
|
2017-11-09 |
2019-05-16 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
EP3505509A1
(en)
|
2017-12-29 |
2019-07-03 |
Université de Liège |
Methods for the preparation of arylcycloalkylamine derivatives
|
CN111836798B
(zh)
|
2018-01-10 |
2022-04-15 |
凯瑞康宁生物工程(武汉)有限公司 |
氯胺酮的前药、其组合物和用途
|
EP3753557A4
(en)
|
2018-02-15 |
2021-12-01 |
National University Corporation Chiba University |
PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
|
WO2019169165A1
(en)
|
2018-02-28 |
2019-09-06 |
Novocine Therapeutics, Llc |
Ketamine and ketamine-related compounds for the treatment of neurological disorders
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
US11426367B2
(en)
|
2018-05-04 |
2022-08-30 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
BR112020023882A2
(pt)
|
2018-06-27 |
2021-02-09 |
Clexio Biosciences Ltd. |
método para tratar transtorno depressivo maior
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
AU2019352028A1
(en)
|
2018-10-05 |
2021-03-11 |
Clexio Biosciences Ltd. |
Dosage regime of esketamine for treating major depressive disorder
|
US20210378989A1
(en)
|
2018-10-11 |
2021-12-09 |
Clexio Biosciences Ltd. |
Esketamine for use in treating major depressive disorder
|
EP3903775A4
(en)
|
2018-12-27 |
2022-10-12 |
National University Corporation Chiba University |
R-KETAMINE AND ITS DERIVATIVE USEFUL AS A PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST A NEURODEVELOPMENTAL DISORDER
|
WO2020143762A1
(en)
|
2019-01-11 |
2020-07-16 |
Alar Pharmaceuticals Inc. |
Ketamine pamoate and use thereof
|
WO2020198039A1
(en)
|
2019-03-23 |
2020-10-01 |
Sermone Sandra |
Ketamine for treatment of sensory processing deficits
|
WO2020212510A1
(en)
|
2019-04-16 |
2020-10-22 |
Janssen Pharmaceutica Nv |
Synthetic methods of preparing esketamine
|
WO2020232274A1
(en)
|
2019-05-15 |
2020-11-19 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
AU2020324432A1
(en)
|
2019-08-05 |
2021-10-07 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
US11007200B2
(en)
|
2019-08-21 |
2021-05-18 |
MediSynergics, LLC |
Cycloalkyl-diamines for the treatment of pain
|
MX2022006596A
(es)
|
2019-12-20 |
2022-07-05 |
Alar Pharmaceuticals Inc |
Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina.
|
IL294202A
(en)
|
2019-12-26 |
2022-08-01 |
Gilgamesh Pharmaceuticals Inc |
History of arylcyclohexylamine and their use in the treatment of psychiatric disorders
|
US20230063459A1
(en)
|
2019-12-30 |
2023-03-02 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
US20230049897A1
(en)
|
2019-12-30 |
2023-02-16 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
WO2021150985A1
(en)
|
2020-01-22 |
2021-07-29 |
Seelos Therapeutics, Inc. |
Reducing side effects of nmda antagonists
|
EP4125836A1
(en)
|
2020-03-27 |
2023-02-08 |
Homeostasis Therapeutics, Limited |
Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
|
JP2023520912A
(ja)
|
2020-04-07 |
2023-05-22 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
|
WO2021231905A1
(en)
|
2020-05-15 |
2021-11-18 |
The University Of Kansas |
Ketamine treatment for amyotrophic lateral sclerosis
|
WO2021252971A2
(en)
|
2020-06-12 |
2021-12-16 |
Bexson Biomedical, Inc. |
Systems and devices for controlled drug delivery
|
WO2021255737A1
(en)
|
2020-06-17 |
2021-12-23 |
Spirify Pharma Inc. |
Hydroxynorketamine analogues, compositions comprising same and methods of use thereof
|